Aprogen Biologics Inc. (KRX: 003060)
South Korea flag South Korea · Delayed Price · Currency is KRW
909.00
+4.00 (0.44%)
Oct 11, 2024, 3:30 PM KST

Aprogen Biologics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Other Revenue
-0---0-0
Upgrade
Revenue
73,63587,36465,19056,48253,32050,904
Upgrade
Revenue Growth (YoY)
-5.14%34.01%15.42%5.93%4.75%12.13%
Upgrade
Cost of Revenue
80,34299,33739,38031,60730,51530,911
Upgrade
Gross Profit
-6,707-11,97425,81024,87522,80519,992
Upgrade
Selling, General & Admin
28,44029,78928,91425,94723,57921,093
Upgrade
Research & Development
20,43715,0002,1871,735697.7336.12
Upgrade
Other Operating Expenses
352357.6365.27416.95592.21343.19
Upgrade
Operating Expenses
71,68558,71630,01528,85023,88521,923
Upgrade
Operating Income
-78,392-70,690-4,204-3,975-1,081-1,930
Upgrade
Interest Expense
-4,408-3,668-274.41-31.14-49.06-3,325
Upgrade
Interest & Investment Income
3,8364,48816,64513,5879,1763,400
Upgrade
Earnings From Equity Investments
86,83479,78694.73352.21,5104,674
Upgrade
Currency Exchange Gain (Loss)
119-6.2233.1612.72-26.11-15.49
Upgrade
Other Non Operating Income (Expenses)
-2,879564.26209.78347.85423.6945,486
Upgrade
EBT Excluding Unusual Items
5,10910,47412,50410,2949,95348,289
Upgrade
Gain (Loss) on Sale of Investments
14,69829,9502,6381,6236,341-50,265
Upgrade
Gain (Loss) on Sale of Assets
-151,526-151,5373.153.08593.480.89
Upgrade
Asset Writedown
-2,271-2,271-264.15-2,134-241.5-553.33
Upgrade
Other Unusual Items
---1.04-4.76-2.67-529.25
Upgrade
Pretax Income
-133,989-113,38314,8819,83116,644-3,057
Upgrade
Income Tax Expense
1,8701,9471,260679.69-2,274409.26
Upgrade
Earnings From Continuing Operations
-135,860-115,33013,6219,15118,918-3,467
Upgrade
Minority Interest in Earnings
4,716-2,940-981.32-1,048-7,665-4,848
Upgrade
Net Income
-131,144-118,27012,6398,10311,253-8,315
Upgrade
Net Income to Common
-131,144-118,27012,6398,10311,253-8,315
Upgrade
Net Income Growth
--55.99%-28.00%--
Upgrade
Shares Outstanding (Basic)
666340403216
Upgrade
Shares Outstanding (Diluted)
666340403216
Upgrade
Shares Change (YoY)
30.86%56.07%1.42%25.52%94.17%66.31%
Upgrade
EPS (Basic)
-1977.60-1874.81312.69203.29354.38-508.42
Upgrade
EPS (Diluted)
-1977.60-1874.81310.00200.00350.00-510.00
Upgrade
EPS Growth
--55.00%-42.86%--
Upgrade
Free Cash Flow
-45,232-61,73924,444-7,0237,112-1,416
Upgrade
Free Cash Flow Per Share
-682.09-978.68604.74-176.20223.97-86.60
Upgrade
Gross Margin
-9.11%-13.71%39.59%44.04%42.77%39.27%
Upgrade
Operating Margin
-106.46%-80.91%-6.45%-7.04%-2.03%-3.79%
Upgrade
Profit Margin
-178.10%-135.38%19.39%14.35%21.10%-16.33%
Upgrade
Free Cash Flow Margin
-61.43%-70.67%37.50%-12.43%13.34%-2.78%
Upgrade
EBITDA
-59,089-49,292-1,800-1,903851.33-269.75
Upgrade
EBITDA Margin
-80.25%-56.42%-2.76%-3.37%1.60%-0.53%
Upgrade
D&A For EBITDA
19,30321,3982,4042,0721,9321,661
Upgrade
EBIT
-78,392-70,690-4,204-3,975-1,081-1,930
Upgrade
EBIT Margin
-106.46%-80.91%-6.45%-7.04%-2.03%-3.79%
Upgrade
Effective Tax Rate
--8.47%6.91%--
Upgrade
Advertising Expenses
-740.041,3717,8004,3434,462
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.